Recursion Pharmaceuticals
RXRX
335 hedge funds and large institutions have $1.03B invested in Recursion Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 61 funds opening new positions, 132 increasing their positions, 81 reducing their positions, and 51 closing their positions.
64% more call options, than puts
Call options by funds: $17.9M | Put options by funds: $10.9M
63% more repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 81
20% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 51
1.37% more ownership
Funds ownership: 63.04% → 64.41% (+1.4%)
0% more funds holding
Funds holding: 334 → 335 (+1)
22% less capital invested
Capital invested by funds: $1.33B → $1.03B (-$294M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$16.7M |
| 2 |
Goldman Sachs
New York
|
+$14.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$12.2M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$11.2M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$10.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$13.9M |
| 2 |
Morgan Stanley
New York
|
-$13.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.68M |
| 4 |
Barclays
London,
United Kingdom
|
-$5.09M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$3.59M |
RXRX Hedge Fund Activity: Q1 2026 in Review
335 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q1 2026, worth a combined $1.03B — down 22% from $1.33B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new RXRX positions and 51 closed out — a net gain of 10 holders — while 132 added to existing stakes and 81 trimmed.
The largest buyer was BlackRock, adding an estimated $16.7M. The largest seller was Citadel Advisors, cutting an estimated $13.9M.
- 335 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q1 2026, up from 334 in Q4 2025.
- Funds reported $1.03B of Recursion Pharmaceuticals stock for Q1 2026, down 22% quarter-over-quarter.
- 61 funds opened new Recursion Pharmaceuticals positions in Q1 2026 and 51 closed out, a net change of +10 holders.
- The largest Recursion Pharmaceuticals buyer in Q1 2026 was BlackRock, an estimated $16.7M added.
- The largest Recursion Pharmaceuticals seller in Q1 2026 was Citadel Advisors, an estimated $13.9M sold.
Based on aggregated 13F filings for Q1 2026.